Blood
Articles in this Issue
Age-related differences in clinical outcomes among hospitalized recipients of CAR-T cell therapy: A national readmission database analysis
Abstract Background: Chimeric antigen receptor T-cell (CAR-T) therapy has revolutionized the treatment of relapsed/refractory hematologic ma...
Interim PET-adapted de-escalation chemotherapy regimen for advanced stage classical Hodgkin lymphoma using brentuximab vedotin, pembrolizumab, doxorubicin, and dacarbazine: Phase 2 study
Abstract Background: Brentuximab vedotin (Bv), Nivolumab (N) and Pembrolizumab (P) have revolutionized the management of advanced stage clas...
Evaluation of low-intensity treatment strategies and outcomes in patients with accelerated Phase and blast Phase myeloproliferative neoplasms: A hero consortium study
Abstract Introduction Patients with accelerated phase or blast phase myeloproliferative neoplasms (AP/BP-MPN) experience...
Assessment of pharmacodynamic efficacy biomarkers from A phase 1, first-in-human study of arlocabtagene autoleucel (arlo-cel) in relapsed and refractory multiple myeloma (RRMM)
Abstract Introduction: The chimeric antigen receptor (CAR) T-cell therapy arlocabtagene autoleucel (arlo-cel; BMS-986393) targets G protein-...
Distinct roles of fetal hematopoietic stem and progenitor cells in building the immune system
Abstract Classically, hematopoietic stem cells (HSCs) were considered the sole source of fetal hematopoietic stem and progenitor cells in th...
Synergistic enhancement of APR-246 anti-leukemic activity through ENO1 inhibition in TP53- and FLT3-mutated Acute Myeloid Leukemia
Abstract Background TP53 mutations occur in 8–17 % of patients with acute myeloid leukemia (AML) and define a high-risk...
Predictors of symptom improvement in myeloproliferative neoplasms: A real-world retrospective cohort study
Abstract Introduction Persistent symptom burden in classic myeloproliferative neoplasms (MPNs) i.e., polycythemia vera (PV), essential thromb...
Targeted base editing enables safe and efficient knockout of ELANE for the treatment of ELANE-associated severe congenital neutropenia
Abstract Severe Congenital Neutropenia (SCN) is a rare hematological disorder characterized by profound neutrophil deficiency and recurrent...
Subgroup analyses from the randomized, Phase 3 VERONA study of venetoclax with azacitidine (Ven+Aza) versus placebo with azacitidine (Pbo+Aza) in patients with treatment-naïve, intermediate and higher-risk Myelodysplastic Syndromes (HR MDS)
Abstract Background: Patients with HR MDS face poor prognosis and are often ineligible for hematopoietic cell transplantation (HCT). After e...
Impact of tumor burden on the risk of cytokine release syndrome (CRS) in patients with multiple myeloma treated with elranatamab (ELRA) in combination with daratumumab (DARA) and lenalidomide (R) in the MagnetisMM-6 trial
Abstract Background MagnetisMM-6 (NCT05623020) is an open-label, 2-arm, randomized, phase 3 study evaluating ELRA in combination with DARA a...
Detection of CPC in peripheral blood after G-CSF mobilization reduces the contamination rate of autologous transplantation stem cell collections for multiple myeloma and explore strategies for graft purification treatment
Abstract Background: Autologous stem cell transplantation (ASCT) remains the standard treatment for patients with multiple myeloma (MM), yet...
Comparable survival outcomes after myeloablative allogeneic stem cell transplantation in secondary and de novo Acute Myeloid Leukemia in first complete remission: A propensity Score–Matched study
Abstract Secondary acute myeloid leukemia (sAML) is a distinct subtype of AML characterized by poor prognosis, arising either from a pre-exi...
Comparative mortality trends of hematological malignancies with and without sepsis among older adults in the United States: A population-based study (1999–2023)
Abstract Introduction: Leukemias, lymphomas, and multiple myeloma are among the hematologic malignancies that pose a significant health burd...
Increased dosing of blinatumomab in children and adolescents with Relapsed/Refractory B-lineage acute lymphoblastic leukemia – beneficial safety profile with 30µg/m²/day in a single center study
Abstract L. G. and C. B. contributed equally. Background: Blinatumomab is a bispecific T-cell engager (CD3/CD19) and the first target-specif...
Delivering CAR-T and bites outpatient: A safe and resource-conscious model for T-cell redirecting therapies
Abstract Background: T-cell redirecting therapies (TCR), including CAR-T and bispecific T cell engagers (BITEs), have ch...
Revumenib for patients with relapsed or refractory (R/R) Nucleophosmin 1–Mutated (NPM1m) Acute Myeloid Leukemia (AML): Outcomes by prior treatment in the phase 2 AUGMENT-101 study
Abstract BACKGROUND NPM1m AML accounts for ~30% of newly diagnosed adult AML and 12% of R/R AML cases. Approximately 50% of adult patients wi...
A continuum of inherited telomere dysfunction links TERT rare variants to age-related diseases
Abstract Background Telomere biology disorders (TBDs) are caused by pathogenic variants in telomerase reverse transcriptase (TERT) and other...
Central nervous system involvement in pediatric Acute Myeloid Leukemia: A comprehensive report from the AML-BFM group
Abstract Background The involvement of the central nervous system (CNS) affects approximately 10% of pediatric patients with acute myeloid le...
Real-world effectiveness of polatuzumab vedotin plus rituximab, cyclophosphamide, doxorubicin and prednisone (R-CHP) compared with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) among elderly Medicare beneficiaries with diffuse large B-cell lymphoma (DLBCL) in the United States
Abstract Background: Polatuzumab vedotin (Pola) plus R-CHP (Pola-R-CHP) has shown a sustained progression-free survival (PFS) benefit over R...
Knockdown of SRSF10 enhances the sensitivity of AML cells to cytosine arabinoside treatment
Abstract Background Cytosine arabinoside (ARA-C) is a major active drug against AML cells, and is widely used also in th...
Prevalence and impact of somatic mutations in patients with aplastic anemia (AA) undergoing allogeneic hematopoietic cell transplantation (HCT): A single center retrospective analysis
Abstract There is accumulating evidence that clonal hematopoiesis is prevalent in acquired AA, a condition where the immune-mediated destruc...
Prognostic impact of mutations in the DNA methylation pathway on clinical outcomes in acute myeloid leukemia: A retrospective cohort study
Abstract Background DNA methylation in CpG islands plays a crucial role in epigenetic regulation and is frequently altered in acute myeloid...
Establishment of differential diagnostic model for ET and pre-PMF based on circulating CD34+ cells and its clinical significance
Abstract Background: Primary myelofibrosis (PMF) and essential thrombocytosis (ET) are common Philadelphia chromosome–negative chronic myelop...
Digestive complications in AML induction: Spotlight on neutropenic enterocolitis
Abstract Intensive chemotherapy (ICT) remains the standard of care for eligible patients with acute myeloid leukemia (AML). ICT-related comp...
Evaluating real-world diagnostic and treatment patterns, risk of thromboembolic events, and mortality for polycythemia vera across an integrated academic-community cancer network
Abstract Background: Polycythemia vera (PV) is a chronic myeloproliferative neoplasm often managed in community settings where access to adv...